Rapid Decline of Serum Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) in Non-Cirrhotic Patients with Chronic Hepatitis C Infection Receiving Direct-Acting Antiviral Therapy

Rapid Decline of Serum Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) in Non-Cirrhotic Patients with Chronic Hepatitis C Infection Receiving Direct-Acting Antiviral Therapy

Direct-acting antivirals (DAAs) efficiently eradicate the hepatitis C virus (HCV). Low-density lipoprotein (LDL) levels increase rapidly upon DAA treatment. Proprotein convertase subtilisin/kexin 9 (PCSK9) induces degradation of the hepatic LDL receptor and thereby elevates serum LDL. The aim of thi...

Full description

Bibliographic Details
Main Authors: Jonathan Grimm, Georg Peschel, Martina Müller, Doris Schacherer, Reiner Wiest, Kilian Weigand, Christa Buechler
Format: Article
Language:English
Published: MDPI AG 2021-04-01
Series:Journal of Clinical Medicine
Subjects:
low-density lipoprotein
liver cirrhosis
Proprotein convertase subtilisin/kexin 9 (PCSK9)
hepatitis C
MELD score
genotype
Online Access:https://www.mdpi.com/2077-0383/10/8/1621

Internet

https://www.mdpi.com/2077-0383/10/8/1621

Similar Items